Sitagliptin (DPP-4 Inhibitor)-induced Rheumatoid Arthritis in Type 2 Diabetes Mellitus: A Case Report

A dipeptidyl peptidase (DPP)-4 inhibitor, commonly used to treat patients with type 2 diabetes, has caused concern because of immune system side effects. We report a 48-year-old woman with type 2 diabetes who was diagnosed with rheumatoid arthritis (RA) after continued polyarthritis and an increase...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Internal Medicine 2012, Vol.51(15), pp.2041-2044
Hauptverfasser:	Yokota, Kazuki, Igaki, Naoya
Format:	Artikel
Sprache:	eng
Schlagworte:	Alleles Arthritis, Rheumatoid - etiology Arthritis, Rheumatoid - genetics Arthritis, Rheumatoid - immunology Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy dipeptidyl peptidase (DPP)-4 inhibitor Dipeptidyl-Peptidase IV Inhibitors - adverse effects Female Genetic Predisposition to Disease HLA-DRB1 Chains - genetics HLA-DRB1 Chains - immunology human leukocyte antigen (HLA) Humans Middle Aged Pyrazines - adverse effects rheumatoid arthritis Rheumatoid Factor - blood Sitagliptin Phosphate Triazoles - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A dipeptidyl peptidase (DPP)-4 inhibitor, commonly used to treat patients with type 2 diabetes, has caused concern because of immune system side effects. We report a 48-year-old woman with type 2 diabetes who was diagnosed with rheumatoid arthritis (RA) after continued polyarthritis and an increase in rheumatoid factor up to 86 IU/mL after three months of treatment with sitagliptin, a DPP-4 inhibitor. The shared epitope (SE)-containing human leukocyte antigen (HLA)-DRB1 alleles, which are important predisposing factors for RA, were positive. RA might have been triggered by sitagliptin due to a predisposing condition.
ISSN:	0918-2918 1349-7235
DOI:	10.2169/internalmedicine.51.7592